Pay in 4 interest-free payments of $5.53 Learn more
Ships within 48 hours · Estimated delivery Oct 30 - Nov 4
Investors allege the company misrepresented its 2025 growth prospects by understating the continuing impact of the "personalization" exception to the compounded GLP-1 exclusion and overstating how many patients would move from compounded products to Novo's branded drugs
GLP-1 medications now contribute approximately 15 percent of monthly revenue at practices offering them, and around 40 percent of GLP-1 patients in 2024 were completely new customers to their practice
Additionally, Table S2 contains information regarding eGFR and electrolyte levels after discontinuation of dialysis
He delivers detailed market assessments, technology adoption studies, and strategic forecasts
& Xu, R
US$ 20.46
US$ 26.54
US$ 24.50
US$ 26.11
US$ 25.54
US$ 26.86
